Table 1 Demographic characteristics of participators at baseline

Age (years)

61.09 ± 1.14

Female, n (%)

96 (40.17)

BMI

22.45 ± 0.33

Smoking, n (%)

42 (17.57)

ICU admission, n (%)

71 (29.71)

ICU stay (days)

3.21 ± 0.65

Comorbidities

Hypertension, n (%)

64 (26.78)

Diabetes mellitus, n (%)

22 (9.21)

Cerebral infarction, n (%)

20 (8.37)

Coronary heart disease, n (%)

11 (4.60)

Bronchitis, n (%)

19 (7.95)

Other disease, n (%)

78 (32.64)

Blood routine

White blood cell (10⁹/L)

8.26 ± 0.27

Neutrophil (10⁹/L)

7.79 ± 0.75

Lymphocyte (10⁹/L)

2.00 ± 0.40

Monocyte (10⁹/L)

0.60 ± 0.04

Eosinophil (10⁹/L)

0.11 ± 0.01

Basophil (10⁹/L)

0.16 ± 0.07

Liver function

Alanine aminotransferase (U/L)

23.00 (15.00, 42.00)

Alanine transaminase (U/L)

25.50 (18.00, 39.50)

Renal function

Urea nitrogen (mmol/L)

5.25 (3.74, 7.20)

Creatinine (μmol/L)

63.00 (48.00, 83.25)

Uric acid (μmol/L)

259.50 (194.50, 347.25)

Myocardial function

Creatine kinase (U/L)

68.00 (37.00, 114.00)

Creatine kinase isoenzyme (U/L)

13.00 (8.00, 20.00)

Lactate dehydrogenase (U/L)

211.00 (157.00, 294.00)

Cardiac troponin I (ng/mL)

0.02 (0.01, 0.05)

Myoglobin (ng/mL)

43.20 (28.25, 96.50)

CURB-65, n (%)

0–1

148 (61.93)

2

50 (20.92)

3–5

41(17.16)

CRB-65, n (%)

0

84 (35.15)

1–2

128 (53.56)

 ≥ 3

27 (11.30)

PSI, n (%)

I (< 50)

54 (22.59)

II (51–70)

61 (25.52)

III(71–90)

55 (23.01)

IV (91–130)

48 (20.08)

V (> 130)

21 (8.79)

CURXO, n (%)

Mild

173 (72.39)

Severe

66 (27.62)

SMART-COP, n (%)

0–2

174 (72.80)

3–4

18 (7.53)

5–6

33 (13.81)

7–8

14 (5.86)

APACHE II , n (%)

 ≤ 4

84 (35.15)

4–6

52 (21.75)

6–10

53 (22.18)

 ≥ 10

50 (20.92)